First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
By Ji-Youn Han, Keunchil Park, Sang-We Kim, Dae-Ho Lee, Hyae-Young Kim, Heung Tae Kim, M. Ahn, T. Yun, J. Ahn, C. Suh and 6 more. Journal of Clinical Oncology, 2012
684 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/1207f0b977fbd95435dc179d2962a0cd466a5120
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “The First-SIGNAL study (41) verified these findings by clinically selecting never smokers with adenocarcinoma then comparing chemotherapy to gefitinib first-line (Table 1).”